Why Zydis® technology?
Metozolv ODT is the only brand of metoclopramide with Zydis® technology. This innovative technology makes it possible for Metozolv ODT to be delivered as an orally disintegrating tablet that rapidly* melts on the tongue and can be taken anywhere, on the go, without liquid. Metozolv ODT featuring Zydis® technology is made in a freeze-drying process—allowing it to rapidly* melt on the tongue, feel smooth, and leave no chalky aftertaste.1
Benefits of Metozolv ODT featuring Zydis® technology
- Rapidly* melts on the tongue
- Can be taken without liquid
- Can be taken anywhere
- Can conveniently be taken when liquid is not available or if swallowing is difficult
Talk to your healthcare professional about Metozolv ODT
If you are currently taking traditional metoclopramide tablets for diabetic gastroparesis or refractory GERD, talk to your healthcare professional about Metozolv ODT and the benefits of orally disintegrating tablets. Metozolv ODT provides a convenient alternative to traditional metoclopramide tablets.
How does Metozolv ODT with Zydis® technology work?
Learn more about Metozolv ODT
*Metozolv ODT disintegrates on the tongue in a median of 53.5 seconds (mean ± standard deviation, 76.8 ± 110.6 seconds).1
Zydis is a registered trademark of Catalent Pharma Solutions.
References: 1. Zydis fast-dissolve technology. Catalent. Available at: http://www.catalent.com/drug/oral/zydis/. Accessed December 5, 2008.
2. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.